UPMC settles $38M whistleblower lawsuit for Medicare fraud

The University of Pittsburgh Medical Center (UPMC) has settled a lawsuit brought by whistleblowers who alleged surgeons at the health system were performing unnecessary procedures to bolster earnings. 

The case will now be settled out of court for $38 million. UPMC does not admit wrongdoing. 

According to coverage in the Pittsburgh Post-Gazette, the lawsuit started in 2012 with a complaint from three UPMC clinicians who sued the health system and 13 staff neurosurgeons, claiming they unfairly billed Medicare for medically unnecessary procedures and received bonus pay as a result. 

The Department of Justice (DoJ) declined to intervene in the case. Related false claim allegations were previously settled in 2016 by UPMC for $2.5 million in fines paid to the government. After which time, the three plaintiffs continued to pursue a new lawsuit on three claims not addressed in that initial settlement. 

The three plaintiffs are set to receive $11 million for moving this second case forward. The payout is a reward to whistleblowers for bringing fraud cases to the attention of the government. The remaining $27 million will be paid by UPMC as a punitive fine to the government directly.  

According to the plaintiffs, the $38 million settlement marks one of the largest false claim recovery judgements on record to not involve the DoJ. 

Read the full story from the Pittsburgh Post-Gazette at the link below.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.